Tracer Biotechnologies is pleased to announce a strategic partnership with Qiagen (QGEN) to co-develop and commercialize minimal residual disease assays for solid tumors on Qiagen’s QIAcuity digital PCR platform. This collaboration aims to deliver highly sensitive, cost-effective, and decentralized MRD testing solutions that enable oncologists to monitor cancer recurrence and guide personalized treatment decisions using minimally invasive blood samples.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QGEN:
- Qiagen N.V. Reports Significant Voting Rights Held by BlackRock
- Qiagen announces strategic partnership with Foresight Diagnostics
- Qiagen expands digital PCR oncology research portfolio
- Citi opens ‘upside 90-day short-term view’ on Qiagen
- Cautious Optimism for Qiagen Amidst Industry Challenges: Awaiting Long-term Growth Assurance